

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on Thursday 9<sup>th</sup> November 2023, I am pleased to confirm the following.

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- CAPOX (Capecitabine with Oxaliplatin)- 2
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)-1
- Lonsurf (Trifluridine - tipiracil)-0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)- 3
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-0
- Any other systemic anti-cancer therapy- 0
- Palliative care only-

**Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- Nivolumab monotherapy or combination with Ipilimumab- 2
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-1
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-2
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)- 1
- Any other systemic anti-cancer therapy- HTrastuzumab maintenance -1, FLOT-2, FOLFIRI -1 , Trifluridine - tipiracil-1
- Palliative care only

**Q3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:**

- Paclitaxel in combination with a platinum-based compound -4
- Platinum-based therapy alone (cisplatin or carboplatin) -0
- Bevacizumab in combination with paclitaxel and carboplatin- 5
- Olaparib -1
- Olaparib + Bevacizumab -0
- Niraparib -4
- Rucaparib -4

**Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:**

This data is not readily available.

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

**Q5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.**

No

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.